01 mmol/kg of gadopentetate dimeglumine
[Magnevist, n = 21] and 10 mL fixed dose of gadoxetic acid [Primovist, n=6]).
enhanced sagittal and axial (SE) T1W (TR, 450-600 msec; TE, 15-20 msec) images were obtained in all patients of intradural tumours.
Patients in this study were injected with intravenous gadopentetate dimeglumine
during imaging of their elbows.
Moreover, cardiodepressive and hypotensive effects caused by gadopentetate dimeglumine
are dose-dependent [24, 26].
The second was a 363-patient Pan-Asian Phase III trial with 120 Japanese patients, which indicated non-inferiority of gadobutrol-enhanced MR images of the body (breast, heart, abdomen, kidney, pelvis and extremity) to those obtained through the use of gadopentetate dimeglumine
Closely related diagnostic agents are gadobenate dimeglumine (MultiHance), gadodiamide (Omniscan), gadofosveset (Ablavar), gadopentetate dimeglumine
(Magnevist), gadoteridol (Prohance), and gadoversetamide (OptiMARK).
For contrast imaging, T1-weighted FLAIR sequences also were obtained after administration of gadopentetate dimeglumine
Patients were injected with 10 mL of a contrast mixture of diluted (2 mmol/L) gadopentetate dimeglumine
(Magnevist; Bayer Schering Pharma AG, Berlin, Germany) according to the standard protocol.
Excretion of gadopentetate dimeglumine
into human breast milk during lactation.
2 mL/kg gadopentetate dimeglumine
at a concentration of 0.
Patients At higher risk * Patients with CKD 4 and 5 (GFR < 30 ml/min) * Patients on dialysis * Patients with acute kidney insufficiency At lower risk * Patients with CKD 3 (GFR 30 - 59 ml/min) Not at risk of NSF * Patients with stable GFR > 60 ml/min) Highest risk of NSF Gadopentetate dimeglumine
(Magnevist plus generic products) Gadodiamide (Omniscan) Gadoversetamide (Optimark) Recommendations for These agents are CONTRA-INDICATED high-risk group in: * patients with CKD 4 and 5 (GFR <30 ml/min), including those on dialysis * acute renal insufficiency * pregnant women * neonates These agents should be used with CAUTION in: * patients with CKD 3 (GFR 30 - 60 ml/min) * There should be at least 7 days between 2 injections.
Dynamic sequences were obtained before and after a standard 20-mL gadopentetate dimeglumine
(Magnevist, Bayer HealthCare Pharmaceuticals, Inc.